STTK
Price
$5.59
Change
+$0.01 (+0.18%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
560.03M
14 days until earnings call
Intraday BUY SELL Signals
TRVI
Price
$12.95
Change
+$0.17 (+1.33%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
1.82B
21 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

STTK vs TRVI

STTK vs TRVI Comparison Chart in %
View a ticker or compare two or three
VS
STTK vs. TRVI commentary
Oct 22, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is STTK is a Hold and TRVI is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for STTK with price predictions
Oct 21, 2026

STTK sees MACD Histogram crosses below signal line

STTK saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 07, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 44 instances where the indicator turned negative. In 42 of the 44 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on STTK as a result. In 86 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where STTK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

STTK broke above its upper Bollinger Band on September 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for STTK entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where STTK's RSI Oscillator exited the oversold zone, 26 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 57 cases where STTK's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.

Following a +7.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where STTK advanced for three days, in 223 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.652) is normal, around the industry mean (2.988). P/E Ratio (-12.682) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (625.000) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. STTK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STTK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for TRVI with price predictions
Oct 21, 2026

TRVI's RSI Indicator recovers from oversold territory

The RSI Oscillator for TRVI moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 25 similar instances when the indicator left oversold territory. In 22 of the 25 cases the stock moved higher. This puts the odds of a move higher at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 60 of 71 cases where TRVI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.

The Moving Average Convergence Divergence (MACD) for TRVI just turned positive on October 20, 2026. Looking at past instances where TRVI's MACD turned positive, the stock continued to rise in 45 of 52 cases over the following month. The odds of a continued upward trend are 87%.

Following a +8.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where TRVI advanced for three days, in 240 of 285 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

TRVI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRVI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for TRVI entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.659) is normal, around the industry mean (2.988). P/E Ratio (-36.486) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 31 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. TRVI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
STTK vs TRVI: Fundamental Ratings
STTK
TRVI
OUTLOOK RATING
1..100
8358
VALUATION
overvalued / fair valued / undervalued
1..100
20
Undervalued
6
Undervalued
PROFIT vs RISK RATING
1..100
10031
SMR RATING
1..100
9795
PRICE GROWTH RATING
1..100
4062
P/E GROWTH RATING
1..100
2219
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TRVI's Valuation (6) in the Pharmaceuticals Major industry is in the same range as STTK (20) in the null industry. This means that TRVI’s stock grew similarly to STTK’s over the last 12 months.

TRVI's Profit vs Risk Rating (31) in the Pharmaceuticals Major industry is significantly better than the same rating for STTK (100) in the null industry. This means that TRVI’s stock grew significantly faster than STTK’s over the last 12 months.

TRVI's SMR Rating (95) in the Pharmaceuticals Major industry is in the same range as STTK (97) in the null industry. This means that TRVI’s stock grew similarly to STTK’s over the last 12 months.

STTK's Price Growth Rating (40) in the null industry is in the same range as TRVI (62) in the Pharmaceuticals Major industry. This means that STTK’s stock grew similarly to TRVI’s over the last 12 months.

TRVI's P/E Growth Rating (19) in the Pharmaceuticals Major industry is in the same range as STTK (22) in the null industry. This means that TRVI’s stock grew similarly to STTK’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
STTKTRVI
RSI
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
N/A
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 11 days ago
86%
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 9 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Oct 22, 2026
Stock price -- (STTK: $5.58 vs. TRVI: $12.77)
Brand notoriety: STTK and TRVI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: STTK: 97% vs. TRVI: 161%
Market capitalization -- STTK: $560.03M vs. TRVI: $1.82B
STTK [@Biotechnology] is valued at $560.03M. TRVI’s [@Biotechnology] market capitalization is $1.82B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $132.95B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

STTK’s FA Score shows that 2 FA rating(s) are green while TRVI’s FA Score has 3 green FA rating(s).

  • STTK’s FA Score: 2 green, 3 red.
  • TRVI’s FA Score: 3 green, 2 red.
According to our system of comparison, TRVI is a better buy in the long-term than STTK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

STTK’s TA Score shows that 3 TA indicator(s) are bullish while TRVI’s TA Score has 5 bullish TA indicator(s).

  • STTK’s TA Score: 3 bullish, 5 bearish.
  • TRVI’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, TRVI is a better buy in the short-term than STTK.

Price Growth

STTK (@Biotechnology) experienced а +4.69% price change this week, while TRVI (@Biotechnology) price change was +5.89% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.02%. For the same industry, the average monthly price growth was -18.10%, and the average quarterly price growth was -15.28%.

Reported Earning Dates

STTK is expected to report earnings on Nov 05, 2026.

TRVI is expected to report earnings on Nov 12, 2026.

Industries' Descriptions

@Biotechnology (-1.02% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
STTK
Daily Signal:
Gain/Loss:
TRVI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

STTK and

Correlation & Price change

A.I.dvisor indicates that over the last year, STTK has been loosely correlated with GHRS. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if STTK jumps, then GHRS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STTK
1D Price
Change %
STTK100%
-4.45%
GHRS - STTK
43%
Loosely correlated
-1.33%
SLDB - STTK
40%
Loosely correlated
+0.16%
CELC - STTK
40%
Loosely correlated
+2.60%
XNCR - STTK
39%
Loosely correlated
+0.88%
TRVI - STTK
39%
Loosely correlated
-0.47%
More

TRVI and

Correlation & Price change

A.I.dvisor indicates that over the last year, TRVI has been loosely correlated with TSHA. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if TRVI jumps, then TSHA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TRVI
1D Price
Change %
TRVI100%
-0.47%
TSHA - TRVI
45%
Loosely correlated
+0.24%
PTGX - TRVI
42%
Loosely correlated
+0.07%
SYRE - TRVI
42%
Loosely correlated
+1.70%
PVLA - TRVI
42%
Loosely correlated
+2.15%
KURA - TRVI
41%
Loosely correlated
-1.00%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NEO17.040.42
+2.53%
NeoGenomics
ARW219.124.19
+1.95%
Arrow Electronics
TELO1.020.01
+0.99%
Telomir Pharmaceuticals
NRC20.31-0.38
-1.84%
National Research Corp
NXL2.03-0.11
-5.14%
Nexalin Technology Inc.